Weight Loss· Peptide
Tirzepatide (Mounjaro / Zepbound)
- Dual GIP/GLP-1
- Weekly
- Larger loss vs. semaglutide
Tirzepatide (Mounjaro / Zepbound) is a once-weekly subcutaneous dual GIP/GLP-1 receptor agonist. In head-to-head trials it produced larger weight loss than semaglutide — averaging ~21% over 72 weeks at the maximum dose. FDA-approved for chronic weight management at BMI ≥30, or ≥27 with a comorbidity.
Typically used for:
Supporting significant weight loss and metabolic improvement in adults with overweight or obesity.
Benefits
What Tirzepatide (Mounjaro / Zepbound) can do for you.
Larger weight loss
Average 15–25% body-weight reduction at one year — larger than semaglutide in head-to-head trials.
Improved metabolic markers
Significant improvements in HbA1c, lipids, and liver enzymes accompany the weight loss.
Better appetite control
Many men report a meaningful reduction in food noise and improved satiety from the first few weeks.
Tirzepatide is a once-weekly subcutaneous injection that activates BOTH the GIP and GLP-1 receptors — a dual mechanism that produces meaningfully larger weight loss than single-receptor GLP-1 agonists like semaglutide in direct comparisons. Eli Lilly markets it as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management).
How it works
GIP and GLP-1 are gut hormones released after eating. Tirzepatide mimics both. GLP-1 activity drives appetite suppression and slowed gastric emptying; GIP activity contributes additional metabolic effects on adipose tissue and insulin response. The combination produces deeper satiety and larger weight loss outcomes than either mechanism alone.
What the evidence supports
The SURMOUNT trials are the FDA-registration data. SURMOUNT-1 showed average weight loss of ~21% on the maximum 15 mg weekly dose over 72 weeks — substantially more than semaglutide's ~15% over a comparable timeframe in STEP.1 SURMOUNT-2 confirmed similar magnitude in patients with type 2 diabetes.2
Who it is for
Zepbound is FDA-approved for adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity.3 Many clinics also offer compounded tirzepatide off-label at lower BMIs at provider discretion — same caveat as compounded semaglutide.
Side effects and trade-offs
- Same GI profile as semaglutide: nausea, constipation, reflux — typically dose-dependent and easing with slow titration.
- Higher rate of vomiting than semaglutide at maximum doses.
- Muscle preservation requires protein + resistance training, same as semaglutide.
- More expensive than generic interventions; coverage varies and compounded shortages have been a 2024–2025 supply issue.
How it works
From consult to follow-up.
Initial consultation
A board-certified physician reviews your symptoms, history, and goals. At many participating clinics the first visit is complimentary.
Baseline labs
Bloodwork tailored to the protocol. Results come back in days, not weeks. We don't prescribe before we have your numbers.
Personalized protocol
Your physician calibrates your dose based on your labs and your goals — not a template. Adjustments happen as your data evolves.
Ongoing follow-up
Recheck visits at six and twelve weeks, then quarterly. Real follow-up, structured into the plan.
- Duration
- Weekly self-injection, ~30 seconds
- Results timeline
- ~7% by week 12; peak loss between months 12–18
Designed around your schedule
Consults are short
Initial visits are typically 45–60 minutes. Many participating clinics waive the fee for new patients.
Telehealth follow-ups
Where state regulations allow, follow-up visits are conducted via telehealth — no extra drive time.
Medication shipped
Prescriptions ship directly from a 503B-licensed pharmacy to your door. No standing in line.
Quarterly check-ins
Real follow-up at six and twelve weeks, then quarterly. Not constant visits, not zero visits.
Pricing
Tirzepatide (Mounjaro / Zepbound), priced honestly.
Both tiers include medication and provider access. Comprehensive adds quarterly lab work and dose titration based on your real numbers — recommended for anyone serious about getting this right.
Starter (Sample)
Titration weeks 1–20
- Compounded tirzepatide (escalating dose)
- Initial consult + intake history
- 6-week side-effect check-in
- Pen + needles included
Maintenance (Sample)
Most popularMaintenance dose (post-titration)
- Compounded tirzepatide at your maintenance dose
- Quarterly physician visits
- Body composition tracking
- Nutrition + resistance-training guidance
Financing
Financing available through CareCredit at participating clinics.
Network providers
34 certified physicians offer Tirzepatide (Mounjaro / Zepbound).
Every provider in the network is board-certified and credentialed.
Brandon Crandall, NP
Men's Health / Erectile Dysfunction · Syracuse, NY
Candace Remington, NP
Men's Health / Erectile Dysfunction · Tampa, FL
Deb Gross, NP
Men's Health / Erectile Dysfunction · Centralia, WA
Dr. Adriana Rosales, MD
Men's Health / Erectile Dysfunction · Seattle, WA
Dr. Aleix Bazzi, MD
Men's Health / Erectile Dysfunction · Beverly Hills, CA
Dr. Amit Grover, MD
Men's Health / Erectile Dysfunction · Seattle, WA
Dr. Ashish Bhavsar, MD
Men's Health / Erectile Dysfunction · Orange County, CA
Dr. Bona Lee, MD
Men's Health / Erectile Dysfunction · Dallas, TX
Dr. Brad Sellers, DO
Men's Health / Erectile Dysfunction · Dallas, TX
Patient reviews — Tirzepatide (Mounjaro / Zepbound)
★★★★★5.0from 1 review
Mike S.
★★★★★Syracuse, NY · Oct 2024
Tirzepatide has been more effective for me than semaglutide was a year ago. Better appetite control, less GI side effects. Down 42 lb.
Source: Internal Sample · Verified
Where to get it
Available in 23 cities.
Pick your metro to see the local clinics, providers, and booking options.
- Beverly Hills, CA2 clinics2 providers
- Dallas, TX2 clinics4 providers
- New York, NY2 clinics2 providers
- Orange County, CA2 clinics2 providers
- Syracuse, NY2 clinics2 providers
- Tampa, FL2 clinics3 providers
- Albany, NY1 clinic1 provider
- Albuquerque, NM1 clinic1 provider
- Boca Raton, FL1 clinic2 providers
- Burlington, ON1 clinic1 provider
- Centralia, WA1 clinic1 provider
- Cleveland, OH1 clinic1 provider
How they compare
Semaglutide vs Tirzepatide
SemaglutideBrand: Wegovy / Ozempic · GLP-1 only | ||
|---|---|---|
| Mechanism | GLP-1 receptor agonist — slows gastric emptying, increases satiety | Dual GLP-1 + GIP receptor agonist — same as semaglutide plus improved insulin sensitivity |
| Typical weight loss at 12 months | ~12–18% body weight | ~15–25% body weight |
| Dose schedule | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Titration | 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over ~16 weeks | 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg over ~20 weeks |
| GI side effects | Nausea, constipation common during titration | Similar profile; some patients tolerate better, some worse |
| CV benefit (established) | Yes — SELECT trial (overweight + established CVD) | Promising but evidence less mature |
| Use in T2 diabetes | Approved (Ozempic) | Approved (Mounjaro) |
| Typical monthly cost | ~$300–500/month at retail | ~$400–600/month at retail |
What sets us apart
Real physicians. Real labs. Real follow-up.
GentsMed is a network of board-certified physicians held to a single clinical standard — built to replace the cash-pay men's-health mills with actual medicine.
- Board-certified physicians.
- Every provider is licensed, NPI-verified, and credentialed by the GentsMed or Urosculpt certification board — no nurse-only prescribers, no offshore consults.
- A single clinical standard.
- Whether you see a urologist in Tampa or a dermatologist in New York, the protocol meets the same criteria.
- Labs-driven, not guess-driven.
- No prescriptions without baseline labs. No cookie-cutter dosing. Quarterly bloodwork is built into the plan.
- Real follow-up.
- Not a 'set it and forget it' Rx mill. Every protocol includes structured follow-up at 6 and 12 weeks, then quarterly.
- Transparent pricing.
- Starting-from prices where we have them, honest "consult for pricing" where we don't. No surprise bills.
- Your records stay with your physician.
- GentsMed is the network. We do not store your PHI. Your clinical data lives with your treating physician, where it belongs.
Frequently asked questions
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. (SURMOUNT-1)(NEJM)
- Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes. Lancet. 2023;402(10402):613–626. (SURMOUNT-2)(PubMed)
- FDA label: Zepbound (tirzepatide) injection, for subcutaneous use.(FDA)
Get started
Talk to a physician about Tirzepatide (Mounjaro / Zepbound).
Every provider in the network is board-certified and credentialed. Find one near you in under a minute.